CEO and President
Richie Cunningham is currently CEO of Icagen Inc. He brings over 20 years of leadership experience in the healthcare and biopharmaceutical industry with Premier Inc., Valeant Pharmaceuticals, Boehringer Ingelheim, and XRpro Sciences Inc. now Icagen Inc.
Mr. Cunningham has experience and depth in a broad array of roles and responsibilities including mergers & acquisitions, business development, strategy development, product launch, contracting, market access, and sales & marketing. His experience includes the commercialization and launch of multiple products in the Infectious Disease, Dermatology, Oncology, Cardiovascular, Respiratory and Diabetes therapeutic areas.
Mr. Cunningham joined Icagen Inc. in late November of 2014 and has since led the company through two transformational acquisitions from Pfizer and Sanofi in July 2015 (Pfizer Carolina Site) and July 2016 (Sanofi Arizona Site). He has led the company from a single technology in XRpro to a research team with leading expertise in the early drug discovery phase. Through these key strategic acquisitions Mr. Cunningham has positioned Icagen as an innovative integrated drug discovery company with unique expertise in the field of ion channel, transporter, neuroscience, muscle biology and rare disease targets while also covering many other classes of drug discovery targets and therapeutic areas.
In addition to establishing his healthcare career, Richie also excelled as a professional athlete in the NFL holding All-Pro honors for the Dallas Cowboys, Green Bay Packers, then later the Carolina Panthers and Jacksonville Jaguars. His career in the NFL spanned from 1994 until his retirement in 2002.